PYC would remain the front runner because its CPPs are far more efficient than other CPPs and AAVs.
To be successful, a drug must have high efficacy, lowest toxicity and gives the patient the best drug administration experience.
Adeno-associated virus (AAV) has an inherent limitation of the size of drug payload. AAV vector genomes have been limited to 5 kilobases (kb) in length because their packaging limit was thought to be similar to the size of the parent AAV genome.
Cell Penetrating Peptide (CPP) when chosen correctly would not have those limitations. PYC has a rich library of billions of CPPs to choose from and the one used in VP-001 is far more superior. Take Sarepta's Exondys-51 as an example, it has to be administered weekly as any higher dosage would cause undesirable side effects due to toxicity. On the other hand, PYC's VP-001 only requires a very small dose of 1 micro gram (0.001 mg) injected into each eyeball every 6 months (26 weeks). DYOR.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)